StreetAlpha.app
Home › Stocks › ABOS

Acumen Pharmaceuticals, Inc. (ABOS)

$0.23
▲ +6.53%
LAST CLOSE · NOV 17

Acumen Pharmaceuticals develops experimental antibody treatments for Alzheimer's disease. It last closed at $0.23 on Nov 17, up 6.53% on the day. ABOS last reported earnings on Mon, Oct 26, 2026. The average 12-month price target from 2 analysts is $1.00 (+334.6% from the last close), with a high of $1.00 and a low of $1.00.

AI Auto Pilots
Is ABOS in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$104.0M
EPS (diluted)
−$1.55
Free cash flow
−$88.0M
Valuation
Market cap
$16.6M
72.3M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$53.1M
At Sep 30
Debt
$5.9M
At Sep 30
Shareholder equity
$34.6M
Shares outstanding
72.3M
At Oct 21
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$100.6M−$100.6MFY2021FY2022: −$42.9M−$42.9MFY2022FY2023: −$52.4M−$52.4MFY2023FY2024: −$102.3M−$102.3MFY2024FY2025: −$121.3M−$121.3MFY2025

From ABOS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 26). Last 12 months adds up the four latest quarters.

Last report
Oct 26
2026 · Before the open (BMO)
Reported EPS
-$0.35
vs -$0.43 est. · beat
Year-ago EPS
—
Not on file
Options-implied move
±32.0%
Priced in before that report
Analyst consensus
1 Buy · 1 Hold
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy · 1 Hold
2firms
1 Buy1 Hold0 Sell
Only 2 firms rated ABOS in the past 90 days, not enough for a consensus
Average 12-month target
$1.00
▲ 334.6% upside

Based on 2 analysts who set a price target on ABOS in the past 90 days. The average target is $1.00, with a high of $1.00 and a low of $1.00, compared with the last close of $0.23.

Low $1.00Avg $1.00High $1.00
Blue marker: last close $0.23
Highest target$1.00
Average target$1.00
Lowest target$1.00
Latest rating changes
BTIGMaintained
Nov 2Buy$1
CitigroupDowngrade
Oct 30Hold$5 → $1
CitigroupMaintained
Sep 15Buy$5
DateFirmActionRatingPrice target
Nov 2BTIGMaintainedBuy$1
Oct 30CitigroupDowngradeHold$5 → $1
Sep 15CitigroupMaintainedBuy$5
Loading…

Technical Analysis

ABOS · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 295% below its 20 day and 652% below its 50 day average. It is 934% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 23), oversold. The nearest support is the Pivot at $0.22, and the nearest resistance the Pivot R1 at $0.24.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 65.2%/day
Key levels
$3.6052 week high+1465.2%
$2.38200 day average+934.8%
$2.17100 day average+843.5%
$1.7350 day average+652.2%
$0.9120 day average+295.7%
$0.25Swing high (Nov 10)+8.7%
$0.24Pivot R1+4.3%
$0.23Last close
$0.22Pivot−4.3%
$0.21Pivot S1−8.7%
$0.1952 week low−17.4%
$0.19Swing low (Nov 5)−17.4%
Indicators
RSI (14)22.50Oversold below 30Oversold
MACD-0.50Below its signal lineBearish
Stochastic1.2Near the bottom of its rangeOversold
ADX (14)41.9Strong downtrend
Williams %R-98.3Oversold below −80, overbought above −20Oversold
CCI (20)-51.7Oversold below −100, overbought above 100Neutral
Rate of change−1.8%Change over 10 sessionsBearish
ATR (14)$0.15Typical daily range, 65.2% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ABOS

What happened before

See how ABOS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ABOS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ABOS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ABOS in the last 90 days.

Loading…

See today’s whale options flow across the market →

ABOS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲38 buying vs 33 selling
  • ▲Held by funds +1.0 pts
  • ▼Funds holding -1
  • ▼Superinvestors: 0 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding9596−1.0%
In funds' top 1000–
Held by funds67.2%66.2%+1.0 pts
New / increased8 / 3030 / 21−25.5%
Reduced / sold out23 / 1015 / 17+3.1%
Put/call ratio0.00––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ABOS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ABOS is in one of them and how their past ABOS trades turned out.

ABOS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ABOS in an article yet. Here's the latest on the wider market.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals is a biopharmaceutical company based in Newton, Massachusetts, that is developing treatments for Alzheimer's disease. Its lead candidate, sabirnetug, is an antibody designed to target soluble amyloid-beta oligomers, which the company believes play a central role in the disease. Sabirnetug is in a Phase 2 trial for people with mild cognitive impairment or mild dementia due to Alzheimer's. The company is also developing a brain-delivery platform with a partner and does not yet have a product on the market.

Headquarters
Newton, MA